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Abstract 
Background: The ability to identify clinically isolated syndrome (CIS) patients at high risk of progression to clinically 
definite multiple sclerosis (CDMS) would be clinically beneficial. The initiation of T cell mediated autoimmune diseases 
such as multiple sclerosis (MS) requires the initial inappropriate activation and differentiation of auto-reactive CD4+ T 
cells. The quiescence of naive T cells is actively maintained by molecules such as TOB1, which control the threshold of 
activation. Upon activation, CD4+ T cells can differentiate into various subsets depending on the milieu present. Th1 
and Th17 cells are strongly implicated in MS, while regulatory T (Treg) cells constrain autoimmune inflammation and 
prevent autoimmunity.
Findings: We therefore investigated the expression of TOB1, CD44 and Treg, Th1 and Th17 transcription factors in 
relation to CIS progression. The expression of TOB1, CD44, FOXP3, TBX21 and RORC genes were measured in CD4+ T 
cells from 10 healthy controls, 20 CIS patients within 3 months of initial clinical presentation and 10 relapsing remit-
ting MS patients sampled within 2 months of relapse. CIS patients were subsequently grouped into those who con-
verted to CDMS within 1 year and those who remained CIS. No differences in the expression of TOB1, CD44, FOXP3 and 
RORC were observed. There was a significant increase in the expression of the Th1 transcription factor Tbet, encoded 
by TBX21, in CIS patients that converted within 1 year compared with those who did not.
Conclusion: This pilot data suggests a role for Th1 cells in CIS progression and warrants further evaluation in a larger 
cohort.
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Background
Clinically isolated syndrome (CIS) refers to the first 
neurological episode caused by central nervous system 
(CNS) demyelination which results in clinical presenta-
tion of a patient. Between 30 and 75 % of CIS patients will 
progress to clinically definite MS (CDMS) (Miller et  al. 
2005; Nilsson et  al. 2005; Optic Neuritis Study Group 
2008), characterised by CNS lesions that are dissemi-
nated throughout the brain and spinal cord, and accumu-
late progressively with time. It would be of great benefit 
to have a biomarker to identify CIS patients with high 
risk of conversion to CDMS as this would facilitate early 
treatment to ultimately delay or prevent clinical conver-
sion to CDMS. No such laboratory biomarker currently 
exists, other than magnetic resonance imaging.
CD4+ T cells play a central role in the pathogenesis of 
MS, and the initial activation of naive auto-reactive CD4+ 
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T cells is thought to be a key step in the initiation of dis-
ease. Both the Th1 and Th17 subsets play a key role in 
MS and its mouse models; Th1 cells produce the cytokine 
IFN-γ while Th17 cells secrete IL-17 (Fletcher et al. 2010).
There are a number of peripheral tolerance mechanisms 
that help to prevent the inappropriate activation of naive 
T cells that are specific for self-antigens. One such toler-
ance mechanism is the requirement for co-stimulation, 
where the ligation of CD28 on the naive T cell with B7.1 
and B7.2 provides the second signal for T cell activation. 
In the absence of an infection, co-stimulatory molecules 
such as B7.1 and B7.2 are not usually expressed by antigen 
presenting cells and this helps to prevent the activation 
of self-antigen specific T cells. Naive T cells are actively 
maintained in a quiescent state by anti-proliferative mech-
anisms. TOB1 (transducer of ERBB2) is constitutively 
expressed in naive T cells and is down regulated upon 
full T cell activation (Tzachanis et  al. 2001). Steady state 
expression of TOB1 controls the threshold of activation 
for CD4 T cells, since in vitro silencing of TOB1 abrogates 
the requirement for co-stimulation and over expression of 
TOB1 inhibited T cell proliferation (Tzachanis et al. 2001). 
In addition, deletion of TOB1 in mice resulted in severe 
CNS autoimmunity (Schulze-Topphoff et  al. 2013) and 
reduced TOB1 expression has been associated with pro-
gression of MS (Corvol et al. 2008). Since TOB1 regulates 
the threshold of activation of naive T cells; acting like a 
brake to ensure cells do not become activated in response 
to inappropriate stimulation, reduced TOB1 expression in 
T cells is implicated in the development and progression 
of autoimmunity (Baranzini 2014). CD44 is a glycoprotein 
expressed at high levels on effector-memory type cells, and 
is involved in migration, adhesion and cell–cell interaction 
(Shimizu et  al. 1989). CD44 ligands include osteopontin, 
hyaluronic acid and collagen (Naor et al. 1997; Weber et al. 
1996). CD44 expression was previously shown in a micro-
array study to be increased, whereas TOB1 expression was 
decreased, in T cells from CIS patients that showed rapid 
progression to CDMS (Corvol et al. 2008).
Therefore in this study we retrospectively examined 
the expression of TOB1 and CD44 in a small pilot cohort 
of CIS patients with different conversion rates in order 
to determine if these markers are sufficient to predict 
CIS patients at high risk of rapid disease progression 
and therefore warrant a larger follow-up study. We also 
measured the gene expression of the transcription factors 
FOXP3, TBX21 and RORC which are the master regula-
tors of Treg, Th1 and Th17 cells respectively.
Methods
Patient information
Patients were identified from an MS patient data-
base in St. Vincent’s University Hospital and invited to 
participate in the study. From the database we gener-
ated lists of all patients meeting the inclusion crite-
ria described below for each arm of the study and then 
randomly selected 10 patients from each group based 
on their anonymised case record number to approach 
regarding participation. Informed consent was obtained 
for all participants. Baseline demographics and diagno-
sis history was recorded. The study population was com-
posed of 4 groups:
1. Patients with CIS and no new clinical or radiological 
disease activity seen after 12 months (n = 10)
2. Patients with CIS who converted to CDMS within 
12 months (n = 10), identified by clinical relapse.
3. Patients with established RRMS who were treatment 
naive and had converted from CIS within 12 months 
(n = 10)
4. Age and sex matched healthy controls (n = 10)
All patients were sampled within 3  months of their ini-
tial episode (if CIS) or within 2  months of a clinically 
confirmed relapse if RRMS. All patients were treatment 
naive at the time of sampling. Ethical approval for this 
study was obtained from the St. Vincent’s University 
Hospital Ethics Committee.
Cell isolation
PBMC were isolated by density gradient centrifugation 
from patients and age and sex matched healthy donors, 
with informed consent. PBMC were cryopreserved for 
later analysis. CD4+ Th cells were magnetically sorted by 
negative selection (Miltenyi Biotech). CD45RO− (naive) 
T cells were then isolated from total CD4+ T cells by 
magnetic depletion of CD45RO+ memory T cells (Milte-
nyi Biotech). The purity of sorted cells was routinely 
>97 %.
RT‑PCR
Expression of TOB1, CD44, Tbet and RORC in total and 
naive CD4+ T cells was examined by RT-PCR. Total RNA 
was extracted from sorted total and naïve CD4+ T cells 
using a miRNeasy extraction kit (Qiagen, Hilden, Ger-
many) and treated with DNase I to eliminate genomic 
DNA contamination. RNA was quantified using the 
NanoDrop (Thermo Scientific). Reverse transcription 
to form cDNA was performed using a High Capacity 
cDNA reverse transcription kit (Applied Biosystems). 
Gene expression was examined with the 7900HT Fast 
Real-Time PCR system (Applied Biosystems) using pre-
designed Taqman gene expression assays with AmpEr-
ase-free TaqMan Universal PCR master mix (Applied 
Biosystems). The appropriate house-keeping gene was 
selected from a panel by geNorm analysis; GAPDH 
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obtained an M-value of less than 1.5 and was, therefore, 
considered stable enough to act as the normalising inter-
nal control in this study. The following primers attached 
to a FAM dye were used; TOB1 (Hs03986111_s1), CD44 
(Hs01075862_m1; exon boundary 1–2 all isoforms), 
FOXP3 (Hs01085834_m1), RORC (Hs01076122_m1) and 
TBX21 (Hs00203436_m1) (all Applied Biosystems). The 
reference gene primer, GAPDH (Hs99999905_m1) was 
conjugated to the VIC dye. The data were normalised to 
GAPDH expression and analysed using SDS 2.3 RQ Man-
ager (Applied Biosystems) software.
The GAPDH crossing threshold (CT) value for indi-
vidual samples was subtracted from the target gene CT 
value. If the GAPDH endogenous control failed to cross 
the threshold after 33 cycles, the sample was excluded. 
The healthy control samples were averaged to use as a 
calibrator and patient data were expressed relative to this. 
Patients with values >1 indicated increased gene expres-
sion and those with results <1 indicated patients with 
decreased gene expression relative to healthy controls.
Statistical analyses were performed using Prism 5 soft-
ware; groups (including healthy controls) were compared 
by two-way ANOVA with a Tukey post-test. p values 
<0.05 were considered significant and denoted in the fig-
ures with an asterisk.
Results
Distribution of patient demographics and onset 
of symptoms in patient sub‑groups
Baseline characteristics, as demonstrated in Table  1 are 
consistent with typical disease characteristics with the 
exception of an over representation of transverse myeli-
tis patients in the non-converting CIS population, how-
ever the numbers of patients in each group are small and 
we do not think this represents any clinically meaningful 
variation from the early conversion group.
The expression of TOB1 and CD44 mRNA in total CD4+ T 
cells and naive CD4+ T cells from CIS patients
Since TOB1 is thought to control the threshold of acti-
vation of CD4+ T cells, we sought to determine whether 
expression of TOB1 was altered in CIS patients that sub-
sequently converted to CDMS within 1  year of initial 
presentation. Total CD4+ T cells and naive CD4+ T cells 
were isolated from cryopreserved PBMC samples; RNA 
was isolated reverse-transcribed into cDNA. The expres-
sion of TOB1 and CD44 was determined by RT-PCR 
relative to the housekeeping gene GAPDH. CIS patients 
were divided into those that subsequently converted to 
CDMS within 1 year of their CIS and those that did not 
convert within 1 year. For comparison, a group of estab-
lished RRMS patients who had previously converted 
to RRMS within 1  year were included. The data were 
normalised relative to a group of age and sex matched 
healthy controls. No significant differences in relative 
expression of TOB1 were observed between CIS patients 
that converted within 1 year, those that did not convert 
and RRMS patients (Fig. 1). However, there was a slight 
trend towards reduced expression of TOB1 in the RRMS 
group.
Similarly, no significant differences in relative expres-
sion of CD44 were observed between CIS patients that 
converted within 1  year, those that did not convert and 
RRMS patients (Fig. 2). Interestingly however, the expres-
sion of CD44 was significantly increased overall in CD4+ 
T cells from patients in all three groups compared to con-
trols (i.e. all relatively higher than 1).
The expression of transcription factors FOXP3, RORC 
and Tbet in CD4+ T cells from CIS patients
Since both Th1 and Th17 subsets of CD4+ T helper cells 
are implicated in the initiation and pathogenesis of MS, 
we also investigated the expression of the transcription 
factors Tbet and ROR-γt (encoded by the RORC gene) 
that act as master regulators for Th1 and Th17 cells, 
respectively. In addition we examined the expression of 
FOXP3, the key transcription factor of Treg cells, which 
help to constrain autoreactive T cells and prevent auto-
immunity. Total CD4+ T cells and naive CD4+ T cells 
were isolated from cryopreserved PBMC samples, RNA 
was isolated and cDNA transcribed. The expression of 
Tbet, RORC and FOXP3 mRNA was determined by 
Table 1 Baseline demographics and symptoms onset in each of the patient sub-groups
CIS clinically isolated syndrome, RRMS relapsing remitting MS, SD standard deviation
CIS—not converted (n = 10) CIS—converted (n = 10) RRMS (n = 10) HC (n = 10)
Mean age at onset (SD) 31.6 (6.4) 27.4 (5.2) 29.7 (6.9) 30.8 (4.6)
Men/women 5/5 3/7 4/6 3/7
Symptom onset
 Optic neuritis (%) 2 (20) 6 (55) 6 (60) N.A.
 Brainstem (%) 3 (30) 3 (27) 2 (20)
 Spinal cord (%) 5 (50) 2 (18) 2 (20)
Page 4 of 6Basdeo et al. SpringerPlus  (2016) 5:779 
RT-PCR relative to the housekeeping gene GAPDH. CIS 
patients were divided into those that had subsequently 
converted to CDMS within 1 year of their CIS and those 
that did not convert within 1  year. For comparison, a 
group of RRMS patients who had previously converted 
to RRMS within 1  year were included. The data were 
normalised relative to a group of age and sex matched 
healthy controls. No significant differences in relative 
expression of RORC or FOXP3 were observed between 
any of the groups (Fig. 3). However, the expression of the 
Th1 transcription factor Tbet was significantly increased 
in CD4+ T cells from CIS patients that had converted 
(p < 0.001) relative to CIS patients that had not converted 
(Fig.  3). There was also a non-significant trend towards 
increased Tbet expression in the RRMS group relative to 
healthy controls and CISnc (Fig. 3).
Discussion
The ability to identify CIS patients at high risk of con-
version to CDMS would facilitate early treatment with 
disease modifying therapies that could prevent their 
progression and potentially improve patient outcomes. 
Since the activation and differentiation of pathogenic 
auto-reactive CD4+ T cells is considered to be a key step 
in the initiation of MS, we investigated the expression of 
key molecules involved in these processes. Interestingly 
we found that the expression of Tbet, the transcription 
factor that regulates the function of Th1 cells, was signifi-
cantly increased in CIS patients who subsequently con-
verted to CDMS within 1 year compared with those who 
had not converted. The expression of Tbet is induced 
during the differentiation of naive CD4+ T cells into Th1 
cells and is induced by the activation of STAT1/4 down-
stream of IL-12 and IFN-γ signalling. Thus our data sug-
gests that the induction of Tbet and differentiation of 
Fig. 1 The expression of TOB1 mRNA in CD4+ T cells from CIS 
patients. The expression of TOB1 was assessed by RT-PCR in naïve 
(black) and total (grey) CD4+ T cells from healthy controls, CIS patients 
within 3 months of their initial episode and RRMS patients within 
2 months of a clinically confirmed relapse who had previously 
converted to CDMS within 1 year. CIS patients were subsequently 
divided into those who converted to CDMS within 1 year (CISc) and 
those that did not convert (CISnc). All values are expressed relative to 
those of healthy controls averaged and set to 1. Statistical differences 
between groups were determined by two-way ANOVA with a Tukey 
post-test, however, results were not significantly different
Fig. 2 The expression of CD44 mRNA in total CD4+ T cells and naive 
CD4+ T cells from CIS patients. The expression of CD44 was assessed 
by RT-PCR in naïve (black) and total (grey) CD4+ T cells from healthy 
controls, CIS patients within 3 months of their initial episode and 
RRMS patients within 2 months of a clinically confirmed relapse who 
had previously converted to CDMS within 1 year. CIS patients were 
subsequently divided into those who converted to CDMS within 
1 year (CISc) and those that did not convert (CISnc). All values are 
expressed relative to those of healthy controls averaged and set to 1. 
Statistical differences between groups were determined by two-way 
ANOVA with a Tukey post-test, however, results were not significantly 
different
Fig. 3 The expression of FOXP3, RORC and Tbet in CD4+ T cells from 
CIS patients. The expression of FOXP3 (black), RORC (grey) and Tbet 
(white) was assessed by RT-PCR in total CD4+ T cells from healthy 
controls, CIS patients within 3 months of their initial episode and 
RRMS patients within 2 months of a clinically confirmed relapse who 
had previously converted to CDMS within 1 year. CIS patients were 
subsequently divided into those who converted to CDMS within 
1 year (CISc) and those that did not convert (CISnc). All values are 
expressed relative to those of healthy controls averaged and set to 1. 
Statistical differences between groups were determined by two-way 
ANOVA with a Tukey post-test; *p < 0.05
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Th1 cells may be associated with CIS conversion, at least 
in a proportion of patients. Th1 cells were originally con-
sidered to be the key pathogenic cell type in MS, how-
ever more recently a role for Th17 cells has also emerged 
(Fletcher et al. 2010). Increased expression of both IFN-γ 
and IL-17, Th1 and Th17 cytokines respectively, have 
been associated with CIS and RRMS (Muls et  al. 2012; 
Frisullo et  al. 2008). We did not however observe any 
significant differences in the expression of RORC, the 
Th17 transcription factor. It is possible however, that 
our approach did not have sufficient sensitivity to detect 
possible alterations in RORC/Th17 cells, since this sub-
set is present in blood at a much lower frequency than 
Th1 cells. Future studies in a larger cohort would benefit 
from the inclusion of additional analyses such as protein 
levels of T cell subset-specific transcription factors and 
cytokine production.
A number of other studies have attempted to identify 
correlates of CIS progression, with the aim of identify-
ing patients at high risk of conversion to CDMS. A study 
by Corvol et  al. used microarrays to study gene expres-
sion in naive CD4+ T cells from 37 CIS patients at time 
of diagnosis and after 1 year. On the basis of changes in 
gene expression at baseline, patients were divided into 4 
groups, and 92  % of group 1 CIS patients converted to 
CDMS within 1  year (Corvol et  al. 2008). Interestingly 
down-regulation of TOB1 and increased CD44 was char-
acteristic of these rapidly progressing group 1 patients; 
however we were unable to replicate these findings in our 
small cohort since we observed no difference in TOB1 or 
CD44 expression between CIS patients that converted 
within 1 year compared with those who did not. Subse-
quently the same group also showed that TOB1−/− mice 
exhibited exacerbated symptoms of experimental auto-
immune encephalomyelitis (EAE), suggesting that TOB1 
has an important role in constraining CNS autoimmun-
ity (Schulze-Topphoff et  al. 2013). The reasons for the 
discrepancy between our data and the studies described 
above are not clear, however it is possible that our cohort 
was not of sufficient size to identify differences in the 
expression of TOB1.
In conclusion this study suggests a possible role for 
increased expression of Tbet in CD4+ T cells as a bio-
marker for early conversion from CIS to CDMS and war-
rants further exploration in larger, longitudinal cohorts.
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